Mobidiag, Isogen Announce Agreement
News Jun 24, 2016
Mobidiag Ltd has announced an agreement with Isogen Life Science for the distribution of the Amplidiag® product line. Under this new agreement Isogen becomes the exclusive distributor of Amplidiag®, in vitro diagnostics for gastrointestinal infections, in Belgium, the Netherlands, Luxembourg and Spain.
“Since Mobidiag’s inception, we have been focusing our activity towards Nordic region and France mainly. We are now in a phase of great expansion and extending our European coverage with the support of reliable partners. In that perspective, we are very pleased to announce our agreement with Isogen Life Science to distribute our Amplidiag® products in high potential markets such as Benelux and Spain” said Tuomas Tenkanen, CEO at Mobidiag.
“Since the molecular diagnostic market has developed as a reliable diagnostic tool, Isogen Life Science has focused on the more niche sample streams within this market. The agreement with Mobidiag enables us to offer our customers a complete solution for the widest spectrum of infections found in such a niche being stool sample. Enabling controlled reliable results from sample to result.” said Martin Donker, CEO at Isogen Life Science.
The distribution agreement with Isogen Life Science is effective immediately and covers all Amplidiag® products (Amplidiag® H. pylori+ClariR, Amplidiag® Stool Parasites, Amplidiag® CarbaR+VRE, Amplidiag® C. difficile+027, Amplidiag® Bacterial GE, Amplidiag® Easy and upcoming Amplidiag® Viral GE).
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019